[
    {
        "file_name": "MusclepharmCorp_20170208_10-KA_EX-10.38_9893581_EX-10.38_Co-Branding Agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "(v)\nDuring\nthe Term and during the sell-off period, MusclePharm shall make royalty payments in U.S.\ndollars for the respective quarters ending on the last day of September,\nDecember, March and June (each, a “Royalty Period”) within\nthirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statement\nshowing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (by\ncountry and customer); (ii) the total number of units returned for which credit was given and the total dollar amount of\nsuch credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemized\nstatement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attached\nherto as Exhibit “B” and furnished to Lender whether or not any Licensed Products were sold during the Royalty\nPeriod.",
                "changed_text": "(v)\nDuring\nthe Term and during the sell-off period, MusclePharm shall make royalty payments in U.S.\ndollars for the respective quarters ending on the last day of September,\nDecember, March and June (each, a “Royalty Period”) within\nthirty (30) days from the end of each quarterly period. Each such royalty payment shall include an itemized statement showing the nature and source of such royalties. Payments are due 90 days after the end of each quarterly period. Each such royalty payment shall include an itemized statement\nshowing the nature and source of such royalties, including (i) the number of units of Licensed Products sold (by\ncountry and customer); (ii) the total number of units returned for which credit was given and the total dollar amount of\nsuch credits, and (iii) the total gross sales and the total royalties due with respect to such gross sales, and each itemized\nstatement shall be certified by a duly authorized officer of MusclePharm. Such statements shall be in the form attached\nherto as Exhibit “B” and furnished to Lender whether or not any Licensed Products were sold during the Royalty\nPeriod.",
                "explanation": "This change introduces an in-text contradiction by stating royalty payments are due both 'within thirty (30) days' and '90 days after the end of each quarterly period'. This creates ambiguity and uncertainty regarding the actual payment deadline, potentially leading to disputes.",
                "location": "Section 7(a)(v)"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "(c)Effect of Expiration/Termination:\nUpon expiration or termination of the Agreement for pursuant to Section 9 herein,\nEndorser shall have no further obligation to render any services whatsoever.\nMusclePharm shall have no further right to use the rights granted to MusclePharm\nhereunder and all such rights (including without limitation the rights to use the Name and\nAppearance Rights and Trademarks) shall immediately and automatically be revoked and shall\nterminate and revert to the AS Parties immediately with no “use-up period”.\nNotwithstanding the foregoing, in the event the expiration of this Agreement or termination of this\nAgreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall be\nentitled to sell-off the remaining Licensed Products for six (6) months after such expiration of this\nAgreement pursuant to paragraph 4(d) herein and shall continue to pay Endorser the Royalty set\nforth in paragraph 7 herein.",
                "changed_text": "(c)Effect of Expiration/Termination:\nUpon expiration or termination of the Agreement for pursuant to Section 9 herein,\nEndorser shall have no further obligation to render any services whatsoever.\nMusclePharm shall have no further right to use the rights granted to MusclePharm\nhereunder and all such rights (including without limitation the rights to use the Name and\nAppearance Rights and Trademarks) shall immediately and automatically be revoked and shall\nterminate and revert to the AS Parties immediately with no “use-up period”.\nNotwithstanding the foregoing, in the event the expiration of this Agreement or termination of this\nAgreement by Musclepharm pursuant to paragraph 9(a), MusclePharm shall be entitled to sell-off the remaining Licensed Products for twelve (12) months after such expiration of this Agreement pursuant to paragraph 4(d) herein and shall continue to pay Endorser the Royalty set forth in paragraph 7 herein.",
                "explanation": "The modification changes the sell-off period from six (6) months to twelve (12) months. This directly contradicts the initial statement in the same section that there is no \"use-up period\" which includes the sell-off rights",
                "location": "Section 9(c)"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "(a)\nMusclePharm shall utilize its commercially reasonable efforts to advertise and promote the Licensed Products at its own expense and to\nsell the Licensed Products through the Distribution Channels worldwide as contemplated herein during the Term and to promote both the goodwill\nof the Endorser and the market reputation of the Licensed Products.\nMusclePharm will conduct its activities relating to the marketing of the\nLicensed Products in a professional manner. In that connection:\n \n(b)\nPrior to the execution and delivery of this Agreement with respect to the First Contract Year and at least ninety (90) days prior to the\nbeginning of each Contract Year of the Term, MusclePharm will provide the AS Parties with a detailed marketing plan (the “Marketing Plan”).",
                "changed_text": "(a)\nMusclePharm shall utilize its commercially reasonable efforts to advertise and promote the Licensed Products at its own expense and to\nsell the Licensed Products through the Distribution Channels worldwide as contemplated herein during the Term and to promote both the goodwill\nof the Endorser and the market reputation of the Licensed Products. MusclePharm makes no guarantees as to the level or type of promotion undertaken, and may elect not to promote the licensed products at all. MusclePharm will conduct its activities relating to the marketing of the\nLicensed Products in a professional manner. In that connection:\n \n(b)\nPrior to the execution and delivery of this Agreement with respect to the First Contract Year and at least ninety (90) days prior to the\nbeginning of each Contract Year of the Term, MusclePharm will provide the AS Parties with a detailed marketing plan (the “Marketing Plan”).",
                "explanation": "By stating “MusclePharm makes no guarantees as to the level or type of promotion undertaken, and may elect not to promote the licensed products at all\", a direct contradiction is created to the previous clause that they will “utilize commercially reasonable efforts to advertise and promote the Licensed Products”. This creates uncertainty about the level of effort expected from MusclePharm and their actual promotional obligations.",
                "location": "Section 12(a)"
            }
        ]
    }
]